The AppNL-G-F mouse retina is a site for preclinical Alzheimer's disease diagnosis and research.
Marjan VandenabeeleLien VeysSophie LemmensXavier HadouxGéraldine GeldersLuca MasinLutgarde SerneelsJan TheunisTakashi SaitoTakaomi C SaidoMurali JayapalaPatrick De BoeverBart De StrooperIngeborg StalmansPeter van WijngaardenLieve MoonsLies De GroefPublished in: Acta neuropathologica communications (2021)
In this study, we report the results of a comprehensive phenotyping of the retina of the AppNL-G-F mouse. We demonstrate that soluble Aβ accumulation is present in the retina of these mice early in life and progresses to Aβ plaque formation by midlife. This rising Aβ burden coincides with local microglia reactivity, astrogliosis, and abnormalities in retinal vein morphology. Electrophysiological recordings revealed signs of neuronal dysfunction yet no overt neurodegeneration was observed and visual performance outcomes were unaffected in the AppNL-G-F mouse. Furthermore, we show that hyperspectral imaging can be used to quantify retinal Aβ, underscoring its potential as a biomarker for AD diagnosis and monitoring. These findings suggest that the AppNL-G-F retina mimics the early, preclinical stages of AD, and, together with retinal imaging techniques, offers unique opportunities for drug discovery and fundamental research into preclinical AD.
Keyphrases
- diabetic retinopathy
- optic nerve
- optical coherence tomography
- drug discovery
- high resolution
- cell therapy
- inflammatory response
- coronary artery disease
- oxidative stress
- stem cells
- high throughput
- type diabetes
- fluorescence imaging
- neuropathic pain
- adipose tissue
- mesenchymal stem cells
- photodynamic therapy
- brain injury
- bone marrow
- subarachnoid hemorrhage
- weight loss